Greg Verdine’s LifeMine raises $263M for safer immunosuppressant
Greg Verdine’s LifeMine raises $263M for safer immunosuppressant
LifeMine Therapeutics
Private
Clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery, which leverages evolutionary insights from fungi to develop next-generation precision medicines. In August 2026 it raised a combined $263 million (Series D + Series F) to support the clinical program for LIFE-001, under development to prevent organ failure.
Company Info
Sector:AI-Driven Drug Discovery / Small Molecule Pharma
Headquarters:Cambridge, Massachusetts, USA
Founded:2017
Website:lifeminetx.com/
Funding Round:Series D + Series F
Total Funding:$263M (2026)
Funding & Investor Relations
Notable Investors
- GV (Google Ventures)
Upcoming Milestones & Key Dates
2026-08
Funding
Combined $263M Series D/F raise announced
Clinical Development Pipeline
LIFE-001
Target: UndisclosedRecent News
LifeMine revived by $188M fundraise backed by Gates and Bezos
LifeMine revived by $188M fundraise backed by Gates and Bezos
LifeMine raises $263M in mission to improve organ transplant aftercare
Organ transplant biotech LifeMine Therapeutics has raised a combined $263 million — a $75 million Series D and an oversubscribed $188 million Series F — to support the clinical program for LIFE-001, under development to prevent organ failure.
Leadership Team
Gregory Verdine
Co-founder, President and CEO